ADMA - NASDAQ

ADMA Biologics, Inc.

ADMA·NASDAQ

$7.93

+2.3%

HealthcareBiotechnology

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.84B

EPS0.6200

P/E Ratio12.80

Earnings Date08/05/2026

624.24M

Assets

28%

3Y+79.0%

5Y+201.0%

10Y+2536.0%

146.92M

Total Liabilities

3Y-25.0%

5Y+23.0%

10Y+422.0%

477.32M

Total Equity

37%

3Y+214.0%

5Y+441.0%

10Y-10809.0%

ADMA Biologics, Inc. Funding & Solvency Profile

ADMA · NASDAQ

Current Assets

Cash & Cash Equivalents87.63M

Net Receivables158.43M

Inventory206.47M

Other Current Assets13.99M

Total Current Assets467 M

Non-Current Assets

Property, Plant & Equipment71.71M

Goodwill & Intangible Assets4.16M

Long-Term Investments0.00

Other Non-Current Assets8.60M

Total Non-Current Assets80 M

Total Assets

624.24M

Financial Health Analysis

Current Ratio

6.71x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.31x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

397 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

75% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

ADMA Biologics, Inc. Balance Sheet

ADMA • NASDAQ

ADMA Biologics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Jun 2011	Jun 2010	Jun 2009	Jun 2008	Jun 2007
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	87.6M	103.1M	51.4M	86.5M	51.1M	55.9M	26.8M	22.8M	43.1M	9.9M	10.4M	17.2M	26.1M	12.5M	8.1K	12K	8.7M	2.6M	14.7M
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4M	6.4M	4.7M	2.9M	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	87.6M	103.1M	51.4M	86.5M	51.1M	55.9M	26.8M	22.8M	43.1M	15.3M	16.8M	21.9M	29.1M	12.5M	8.1K	12K	8.7M	2.6M	14.7M
Net Receivables	158.4M	50M	27.4M	15.5M	28.6M	13.2M	3.5M	1.4M	3.9M	1M	924.5K	384K	0.0	39.1K	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	158.4M	50M	27.4M	15.5M	28.6M	13.2M	3.5M	1.4M	3.9M	1M	924.5K	384K	0.0	39.1K	0.0	0.0	0.0	0.0	0.0
Inventory	206.5M	170.2M	172.9M	163.3M	124.7M	81.5M	53.1M	18.6M	12.6M	5M	3.4M	1.7M	1.7M	1.3M	0.0	3.4M	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	4.3M	3M	2.5M	1.8M	1.2M	313.9K	111K	143.6K	298.7K	107.8K	0.0	0.0	0.0	0.0	0.0
Other Current Assets	14M	8M	5.3M	5.1M	0.0	0.0	0.0	1.8M	2.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	466.5M	331.4M	257M	270.4M	208.7M	153.7M	85.8M	44.5M	63.2M	21.7M	21.3M	24.1M	31.1M	13.9M	8.1K	12K	8.7M	2.6M	14.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	71.7M	63.3M	63.5M	68.7M	58.2M	45.9M	33M	30.1M	30.5M	2M	2.4M	2.8M	765.3K	779.3K	0.0	1.1M	0.0	0.0	0.0
Goodwill	3.5M	3.5M	3.5M	3.5M	3.5M	3.5M	3.5M	3.5M	3.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	632K	460K	499K	1M	1.7M	2.4M	3.2M	4M	4.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	4.2M	4M	4M	4.5M	5.3M	6M	6.7M	7.5M	8.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	400K	0.0	0.0	0.0
Tax Assets	73.3M	84.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.5M	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	8.6M	5.7M	4.7M	4.8M	4.1M	2.1M	1.6M	6.7M	6M	27.2K	27.2K	298.8K	162.2K	-12.7M	0.0	0.0	0.0	0.0	0.0
Total Non-Current Assets	157.7M	157.3M	72.2M	78.1M	67.5M	53.9M	41.3M	44.3M	44.9M	2M	2.4M	3.1M	927.5K	1.6M	0.0	1.5M	0.0	0.0	0.0
Other Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-1.5M	0.0	0.0	0.0
Total Assets	624.2M	488.7M	329.2M	348.5M	276.3M	207.7M	127.1M	88.9M	108M	23.7M	23.7M	27.2M	32M	15.6M	8.1K	12K	8.7M	2.6M	14.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	22.5M	23.7M	15.7M	13.2M	12.4M	11.1M	9.2M	5.9M	5.9M	2.6M	2.1M	1.8M	2.7M	1.1M	0.0	842.2K	0.0	0.0	0.0
Accounts Payable	22.5M	20.2M	15.7M	13.2M	12.4M	11.1M	9.2M	5.9M	5.9M	2.6M	2.1M	1.8M	2.7M	1.1M	0.0	842.2K	0.0	0.0	0.0
Other Payables	0.0	3.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	28.6M	30.6M	23.2M	1.2M	8.2M	4.5M	3.6M	3.4M	2.4M	2M	2.3M	860.1K	747.1K	5.3K	9.8K	12.4K	0.0	0.0
Short Term Debt	3.9M	0.0	0.0	0.0	0.0	0.0	0.0	30K	0.0	6.1M	15.1K	13.8K	12.7K	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	1.2M	1M	905K	591.1K	365.7K	229.1K	30K	0.0	16.6K	15.1K	0.0	0.0	11.6K	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	3.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-617.6K	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	1.4M	143K	182K	143K	142.8K	142.8K	142.8K	142.8K	142.8K	145.2K	145.2K	75.6K	75.6K	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	41.7M	1.9M	2.4M	1.8M	16M	207.3K	0.0	-60K	0.0	0.0	-30.3K	0.0	0.0	0.0	0.0	-797.5K	0.0	16M	10.1M
Total Current Liabilities	69.5M	55.5M	49.8M	39.3M	30.4M	19.9M	14M	9.6M	9.4M	11.2M	4.2M	4.2M	3.7M	1.8M	5.3K	12.4K	11.5M	16M	10.1M
NON-CURRENT LIABILITIES
Long Term Debt	76M	72.3M	130.6M	142.8M	94.9M	93M	83.2M	44.1M	43M	14.1M	15.7M	14.9M	5M	3.9M	0.0	100K	0.0	16M	10.1M
Deferred Revenue (Non-Current)	0.0	1.5M	1.7M	1.8M	2M	2.1M	2.3M	2.4M	2.5M	2.7M	2.8M	1.5M	1.6M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-40.5M	0.0	-8M	-16.3M	83.2K	-3.8M	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	1.4M	1.7M	2.1M	1.9M	397.4K	54.9K	106.6K	12.9M	12.7M	117.8K	92.4K	560K	105.4K	356.9K	0.0	-100K	0.0	0.0	0.0
Total Non-Current Liabilities	77.4M	84.1M	144.2M	157.2M	104.7M	99.5M	86.9M	59.5M	58.2M	16.9M	18.7M	17M	6.7M	4.3M	0.0	200K	11.5M	16M	10.1M
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-200K	-14.3M	-29.3M	-5.5M
Capital Lease Obligations	0.0	9.8M	10.8M	11.6M	8.1M	4.7M	1.5M	149.1K	0.0	36.3K	51.4K	65.2K	77.9K	89.5K	0.0	0.0	0.0	0.0	0.0
Total Liabilities	146.9M	139.7M	194M	196.5M	135.1M	119.4M	100.9M	69.1M	67.7M	28.1M	22.9M	21.2M	10.4M	6.1M	5.3K	12.4K	8.7M	2.6M	14.7M
SHAREHOLDERS' EQUITY
Common Stock	24K	24K	23K	22K	19.6K	10.5K	5.9K	4.6K	4.5K	1.3K	1.1K	929.0	929.0	462.0	250.0	250.0	250K	250K	0.0
Additional Paid-In Capital	0.0	657.6M	641.4M	630M	553.3M	428.7M	290.9M	236.2M	191M	102.5M	88.2M	75.5M	74.2M	46.5M	156.1K	138.5K	113K	0.0	0.0
Retained Earnings	-161.7M	-308.6M	-506.3M	-478M	-412.1M	-340.5M	-264.7M	-216.4M	-150.7M	-106.9M	-87.4M	-69.4M	-52.6M	-37.1M	-153.6K	-113.6K	0.0	0.0	0.0
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-3.4M	-1.3M	-2.2M	-1.8M	-1.3M	-1M	0.0	0.0	-500K	0.0	0.0	0.0
Other Total Stockholders' Equity	638.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	125.0	0.0	500K	-3.2M	-13.6M	4.6M
Total Stockholders' Equity	477.3M	349M	135.2M	152M	141.2M	88.2M	26.2M	19.8M	40.3M	-4.5M	821K	6M	21.6M	9.4M	2.8K	-346.0	-2.8M	-13.3M	4.6M
Total Equity	477.3M	349M	135.2M	152M	141.2M	88.2M	26.2M	19.8M	40.3M	-4.5M	821K	6M	21.6M	9.4M	2.8K	-346.0	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	624.2M	488.7M	329.2M	348.5M	276.3M	207.7M	127.1M	88.9M	108M	23.7M	23.7M	27.2M	32M	15.6M	8.1K	12K	8.7M	2.6M	14.7M
Total Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4M	6.4M	4.7M	2.9M	0.0	0.0	400K	0.0	0.0	0.0
Total Debt	79.9M	82.1M	141.4M	154.4M	102.9M	97.7M	84.7M	44.2M	43M	20.3M	15.7M	15M	5.1M	4M	0.0	7.2M	11.5M	16M	10.1M
Net Debt	-7.7M	-21M	90.1M	67.9M	51.8M	41.7M	58M	21.5M	-136.7K	10.3M	5.3M	-2.2M	-21.1M	-8.6M	-8.1K	7.2M	2.8M	13.3M	-4.6M
Shares Outstanding	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765	237,997,765

SEC Filings

ADMA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	June 02, 2026	June 02, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 15, 2026	June 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 27, 2026	March 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 02, 2026	March 02, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing

Showing 1 to 10 of 380 filings

Related Guides

Blog Categories

Continue your ADMA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.